Literature DB >> 1500387

Oncogenes in ovarian cancer.

A Berchuck1, M F Kohler, R C Bast.   

Abstract

The discovery of cancer-causing genes has provided us with the exciting opportunity to begin to understand the molecular pathology of ovarian cancer. Activation of several of these genes including HER-2/neu, myc, ras, and p53 has been described in some ovarian cancers (Table 2). In addition, some proto-oncogenes such as the EGF receptor (erbB) and the M-CSF receptor (fms) are expressed along with their respective ligands in some ovarian cancers. Finally, for every oncogene that has been studied in ovarian cancer, there are at least a half-dozen that remain unexplored. In the future, when we have a better understanding of the molecular pathology involved in the development of ovarian cancer, this may allow us to better diagnose and treat, and eventually prevent, ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1500387

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  5 in total

1.  Effects of sialidase NEU1 siRNA on proliferation, apoptosis, and invasion in human ovarian cancer.

Authors:  Li-rong Ren; Li-ping Zhang; Shu-ying Huang; Yuan-fang Zhu; Wen-juan Li; Shan-yu Fang; Li Shen; Yan-ling Gao
Journal:  Mol Cell Biochem       Date:  2015-10-13       Impact factor: 3.396

2.  A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.

Authors:  Edwin M Posadas; Meghan S Liel; Virginia Kwitkowski; Lori Minasian; Andrew K Godwin; Mahrukh M Hussain; Virginia Espina; Bradford J Wood; Seth M Steinberg; Elise C Kohn
Journal:  Cancer       Date:  2007-04-01       Impact factor: 6.860

Review 3.  A Brief Overview of Oncogenes and Signal Transduction Pathways in Gynecological Cancer.

Authors:  Emmanuel N Kontomanolis; Antonios Koutras; Zacharias Fasoulakis; Athanasios Syllaios; Michail Diakosavvas; Kyveli Angelou; Panagiotis Symeonidis; Athina A Samara; Vasilios Pergialiotis; Nikolaos Garmpis; Dimitrios Schizas; Athanasios Pagkalos; Athanasios Chionis; Georgios Daskalakis; Thomas Ntounis
Journal:  Cancer Diagn Progn       Date:  2022-03-03

Review 4.  Oncogenes associated with drug resistance in ovarian cancer.

Authors:  Xia Liu; Yutao Gao; Yi Lu; Jian Zhang; Li Li; Fuqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-06       Impact factor: 4.553

Review 5.  The genetic analysis of ovarian cancer.

Authors:  A N Shelling; I E Cooke; T S Ganesan
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.